卡地纳健康Q2财报超预期，机构上调目标价

Core Viewpoint - Cardina Health reported Q2 FY2026 revenue of $65.627 billion and net profit of $4.67 billion, both showing year-on-year growth and exceeding market expectations [1][2]. Financial Report Analysis - For Q2 FY2026, Cardina Health achieved revenue of $65.627 billion, representing an 18.75% year-on-year increase; net profit reached $4.67 billion, up 16.75% year-on-year. The growth was primarily driven by the pharmaceutical distribution business, although the gross margin was 3.52% and net margin was 0.71%, reflecting the low-margin nature of the industry. The revenue surpassed market expectations of $64.9381 billion, with earnings per share at $2.63, exceeding the forecast of $2.37 [2]. Institutional Perspectives - TD Cowen maintained a "Buy" rating for Cardina Health on February 11, 2026, raising the target price from $233 to $251 based on the better-than-expected performance and industry outlook. Among 20 institutions covering the stock in February, 80% rated it as "Buy" or "Hold," with an average target price of $251.13. The internal database indicates a forecast of $2.63 for Q2 earnings per share, reflecting a year-on-year increase of 36.27% [3]. Recent Events - The Q2 performance was disclosed on February 5, 2026. TD Cowen raised the target price on February 11, coinciding with a 1.05% overall increase in the healthcare sales sector [4]. Recent Stock Performance - Over the past 7 days (February 5 to 11), the stock price fluctuated by 4.94%, with a high of $230.81 on February 6 and a low of $219.58 on February 10. The closing price on February 11 was $224.25, reflecting a single-day increase of 1.81% with a trading volume of 1.3133 million shares. On February 6, trading volume peaked at 2.2507 million shares, indicating active trading that later declined. The internal database shows a price change of -1.29% during this period, primarily influenced by post-earnings volatility [5].